SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC（SYNSTAR 04）

This study was an open-label, multi-center, randomized phase III study to evaluate the efficacy and safety of SYS6010 combined with Enlonstobart versus Immunotherapy+ Platinum-based chemotherapy as First-Line treatment for patients with PD-L1-Positive locally advanced or metastatic NSCLC.

NCT Number	NCT07633873
Lead Sponsor	CSPC Megalith Biopharmaceutical Co.,Ltd.
Conditions	Non-Small Cell Lung Cancer
Enrollment	500 participants
Start Date	2026-06-02
Primary Completion	2027-09-30 (estimated)
Study Completion	2029-05-30 (estimated)
Updated on ClinicalTrials.gov	2026-06-11